Perspective Therapeutics (CATX) EBT Margin (2010 - 2023)

Perspective Therapeutics (CATX) posted EBT Margin of 158.57% for Q4 2023, up 136.2% sequentially from 438.08% in Q3 2023.

Perspective Therapeutics (CATX) EBT Margin (2010 - 2023) Analysis & Trends

Perspective Therapeutics has reported EBT Margin for 14 years, with the latest figure at 158.57% in Q4 2023.

Quarterly EBT Margin changed N/A year-over-year to 158.57% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 4456.5% (changed N/A YoY) and the FY2023 annual result came in at 2796.79%, changed N/A from the prior year.
EBT Margin climbed to 158.57% in Q4 2023 per CATX's latest filing, from 438.08% in the prior quarter.
Over five years, EBT Margin peaked at 158.57% in Q4 2023 and troughed at 632.4% in Q2 2023.
A 5-year average of 121.91% and a median of 59.2% in 2019 frame the typical range for EBT Margin.
The sharpest annual moves came in 2019 and 2023: EBT Margin surged 9319 bps in 2019, then plunged 56915 bps in 2023.
Over 5 years, EBT Margin stood at 59.61% in 2019, then advanced by 19 bps to 47.99% in 2020, then retreated by 19 bps to 56.96% in 2021, then sank by 84 bps to 105.06% in 2022, then jumped by 251 bps to 158.57% in 2023.
According to Business Quant data, EBT Margin over the past three periods registered 158.57%, 438.08%, and 632.4% for Q4 2023, Q3 2023, and Q2 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Abbott Laboratories	200.19 Bn	194.59 Bn	7.27 Bn	12.10%
2	Stryker	129.95 Bn	126.47 Bn	4.50 Bn	23.74%
3	Medtronic	120.06 Bn	110.84 Bn	6.41 Bn	18.70%
4	Boston Scientific	74.14 Bn	73.60 Bn	3.85 Bn	19.48%
5	Edwards Lifesciences	52.74 Bn	48.49 Bn	1.35 Bn	29.86%
6	Dexcom	34.60 Bn	32.65 Bn	830.00 Mn	24.27%
7	GE HealthCare Technologies	34.20 Bn	32.10 Bn	2.18 Bn	13.09%
8	Koninklijke Philips	26.46 Bn	23.13 Bn	4.55 Bn	8.91%
9	Steris	23.25 Bn	22.77 Bn	684.20 Mn	18.32%
10	Perspective Therapeutics	388.50 Mn	388.50 Mn	-	-

Download Data